Drug firm Lupin today said it has received final approval from the US health regulator to market its Clonidine Hydrochloride extended release tablets used for treatment of attention deficit hyperactivity disorder.
The company has received USFDA's final approval to market the tablets in the strength of 0.1 mg, Lupin said in a filing to BSE.
The product is generic version of Concordia Pharmaceuticals Inc's Kapvay extended-release tablets in the same strength, it added.
As per the IMS MAT June 2017 data, the tablets had annual sales of around USD 66 million in the US, Lupin said.
The tablets are "indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications", it added.
Shares of Lupin ended at Rs 997.10 per scrip, down 0.66 per cent from its previous close on BSE today.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)